ERBB2 and breast carcinoma: It has been reported that trastuzumab, a monoclonal recombinant antibody targeting HER2 that is commonly used to treat HER2-positive breast cancer, reduces the expression of SDC4 in anoikis-resistant endothelial cells [17].